World Equity Group Inc. Invests $342,000 in Zoetis Inc. (NYSE:ZTS)

World Equity Group Inc. purchased a new stake in Zoetis Inc. (NYSE:ZTS - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 2,099 shares of the company's stock, valued at approximately $342,000.

Several other large investors have also added to or reduced their stakes in ZTS. Mizuho Securities USA LLC lifted its position in Zoetis by 13,726.9% in the 3rd quarter. Mizuho Securities USA LLC now owns 4,865,000 shares of the company's stock valued at $950,524,000 after acquiring an additional 4,829,815 shares in the last quarter. Assenagon Asset Management S.A. boosted its stake in shares of Zoetis by 296.9% in the 4th quarter. Assenagon Asset Management S.A. now owns 889,444 shares of the company's stock worth $144,917,000 after buying an additional 665,331 shares during the last quarter. Nordea Investment Management AB boosted its stake in shares of Zoetis by 38.3% in the 4th quarter. Nordea Investment Management AB now owns 2,065,514 shares of the company's stock worth $336,266,000 after buying an additional 572,511 shares during the last quarter. Holocene Advisors LP purchased a new position in shares of Zoetis in the 3rd quarter worth approximately $110,809,000. Finally, Fisher Funds Management LTD purchased a new position in shares of Zoetis in the 4th quarter worth approximately $66,123,000. Institutional investors own 92.80% of the company's stock.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on ZTS. Morgan Stanley cut their target price on Zoetis from $243.00 to $238.00 and set an "overweight" rating on the stock in a research note on Friday, February 14th. Piper Sandler upped their price objective on Zoetis from $200.00 to $205.00 and gave the company an "overweight" rating in a research note on Thursday. Leerink Partners began coverage on shares of Zoetis in a report on Monday, December 2nd. They set an "outperform" rating and a $215.00 target price on the stock. UBS Group assumed coverage on shares of Zoetis in a report on Monday, December 9th. They set a "neutral" rating and a $196.00 target price on the stock. Finally, Barclays upped their price target on shares of Zoetis from $242.00 to $244.00 and gave the stock an "overweight" rating in a report on Friday, February 14th. Two equities research analysts have rated the stock with a hold rating, nine have assigned a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Buy" and a consensus target price of $215.90.

Remove Ads

Insider Buying and Selling at Zoetis

In related news, EVP Roxanne Lagano sold 326 shares of the firm's stock in a transaction that occurred on Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total value of $55,804.68. Following the sale, the executive vice president now owns 16,107 shares in the company, valued at approximately $2,757,196.26. This trade represents a 1.98 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 0.16% of the company's stock.

Zoetis Trading Down 0.0 %

ZTS stock traded down $0.04 during trading on Thursday, reaching $164.95. The company had a trading volume of 2,253,450 shares, compared to its average volume of 3,282,654. Zoetis Inc. has a 52 week low of $144.80 and a 52 week high of $200.53. The company has a market cap of $73.86 billion, a P/E ratio of 30.16, a PEG ratio of 2.78 and a beta of 0.90. The business has a 50 day moving average of $166.22 and a 200 day moving average of $177.58. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.75 and a quick ratio of 1.08.

Zoetis (NYSE:ZTS - Get Free Report) last released its quarterly earnings results on Thursday, February 13th. The company reported $1.40 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.37 by $0.03. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The company had revenue of $2.32 billion during the quarter, compared to the consensus estimate of $2.30 billion. As a group, sell-side analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be paid a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.21%. The ex-dividend date of this dividend is Monday, April 21st. Zoetis's dividend payout ratio is 36.56%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.